Phagicin, which is an antiviral agent active against deoxyribonucleic acid (DNA) viruses such as vaccinia and herpes simplex, has been identified as a phage internal protein. It was found in infected Escherichia coli lysates, but could also be obtained by disruption of the purified infective particles after incubation with LiCl at 46 C for 15 min or by sonic treatment. After centrifugation at high speed, the antiviral activity was found in the DNA phase and could be separated by chromatography on Sephadex gels with 0.2 M phosphate buffer (pH 7.5) as the eluent. Phagicin present in lysates after removal of infective particles was nondialyzable and was bound to nucleic acids. It could be released during precipitation of nucleic acids by streptomycin sulfate, and in this form it could be easily dialyzed. The antiviral activity of phagicin was specific for herpes simplex and vaccinia viruses.
When Escherichia coli is infected with the temperate phage X, a soluble protein which inhibits herpes simplex growth in vivo and in vitro is produced (3) . This material does not interfere with adsorption of the virus but acts at the stage of intracellular replication. Because such material is not found in measurable amounts in uninfected E. coli culture and its production is closely associated with phage replication, the term "phagicin" was proposed for this antiviral agent. The initial problem was to isolate the material, define its chemical nature, and determine its relationship and specificity to X phage replication. This communication describes the isolation and purification of this material from E. coli K-12 cultures after infection with X and X b2b5c coliphages.
MATERIALS AND MErHODS
Bacterial strains. The procedures used for the propagation of E. coli K-12 have been described previously (3) . The cultivation and induction of E. coli K-12 (X) was performed by the method of Korn et al. (7) .
Bacteriophages. The procedure for the cultivation of X phage has been described (3) . A virulent mutant strain, X b2b5c, was propagated in the same medium without agar. Purified phage stocks were prepared in the following way. The bacteria and debris were removed from the lysates by centrifugation at 37,000 X g for 30 min. After filtration through a 0.45 ifilter (Millipore Corp., Bedford, Mass.), the supernatant fluid was centrifuged at 105,000 X g for 5 hr. The pellet was suspended in 0.05 M tris(hydroxymethyl)-aminomethane (Tris)-chloride buffer (pH 7.5) and was chromatographed in a Sagarose 2 gel column equilibrated with the same buffer. The fractions containing the bacteriophage were filtered and stored at 4 C.
The phage stock used for the preparation of rabbit antiserum was prepared by banding the phage in a CsCl gradient according to the method of Kaiser et al. (5) . Intramuscular injections of phage mixed with Freund's adjuvant were given for 3 consecutive weeks, and blood was collected at the fourth week. The titer of the antiphage serum was determined by standard neutralization tests as described by Adams (1), and the "serum blocking" tests were conducted according to the method of Stent (10) . Phage particles were disrupted either by sonic treatment in the cold with a Branson Instrument Sonifier or by the use of LiCl as described by Dyson (4) .
Virus strains. The medium used for growth of herpes simplex strain GCA3 on chick embryo fibroblasts has been described elsewhere (3) .
Antiviral assay. The antiviral activity of the crude lysate and the purified fractions was studied by the plaque inhibition assay as previously reported (3) . Units of phagicin were expressed as the reciprocal of the dilution which inhibits the plaque count by onehalf. The specific activity was expressed as units/ug of protein. The in vivo assay was performed according to the method of Kaufman (6) with rabbit corneas. Virus was inoculated into the rabbit corneas; 48 hr after infection, the animals were randomized into similar groups of 12. The material tested was applied every 2 hr, and the ulcers were evaluated at the third day of treatment. The scoring was done in the follow- ultraviolet irradiation, thus eliminating a nucleic acid macromolecule (3) . The loss of antiviral activity after treatment with proteolytic enzymes indicated that the activity resided in a protein moiety.
Trypsin. The crude lysate was incubated with trypsin for 18 hr, as described in Materials and Methods. Incubation with trypsin resulted in a total loss of antiviral activity (Table 1) .
Pepsin. The effect of pepsin on fraction I (see Purification) was also investigated. It was observed that incubation of 5 ml of fraction I with 1 ml of pepsin solution resulted in partial loss of antiviral activity (Table 1) . Similar experiments with longer incubation periods resulted in greater losses of activity. It can be concluded from these experiments that the antiviral activity resides in the protein moiety.
Production of phagicin. Phagicin is produced in E. coli upon infection with the bacteriophage X, and it is released in the medium after lysis of the Samples of noninduced and induced culture were taken and agitated with chloroform. Both samples were spun down to remove cell debris, and then were centrifuged at 30,000 rev/min for 1 hr. Gel filtration of both samples of equal protein content was done in Sephadex G-100. As shown in Fig.  2 , peak 1 (see Antiviral activity) is present in the induced sample, in contrast to the small amount of material present in the noninduced control; this can be accounted for by the spontaneous replication of X phage in the noninfected culture which is in the order of 102 plaque-forming units (PFU)/ml. Table 2 shows the results of the assay for antiviral activity in both induced and noninduced lysates. The activity is found mainly in the induced sample. The experiment above showed that phagicin is dependent on phage replication.
Since the preceding experiment shows that phagicin is dependent on phage replication, it seemed necessary to determine at what time during phage replication phagicin is produced.
In this experiment, 20 ml of E. coli (107 cells per ml) was mixed with 20 ml of phage inoculum (105 PFU/ml) and allowed to adsorb for 10 min at 37 C with agitation. After adsorption, the culture was diluted to 2,000 ml with broth. Samples of the culture were removed at different times and agitated with chloroform. A small amount of each sample was saved for phage count. All samples were spun down to remove debris, passed through a filter (Millipore Corp.), concentrated two times, and tested in tissue culture for antiviral activity. The results (Fig. 3) indicate that phagicin is produced after infection, reaches a peak a few minutes prior to the first burst of phage particles, and decreases somewhat concomitantly with phage liberation. A similar bacterial inoculum not infected with X phage and grown under the same conditions showed no antivirl activity. An effort was made to find out whether phagicin could be obtained from whole infective phage. Phage was disrupted with LiCl, as described in Materials and Methods. The uncentrifuged shocked sample was then chromatographed in a G-25 column with water or 0.1 M phosphate buffer (pH 7.5) as the eluent. With the latter, a precipitate was observed indicating the position of Li in the column. The pattern obtained is shown in Fig. 4 . All of the fractions obtained were tested in tissue culture and the antiviral activity was found in the last peak. The position of the last This fraction was lyophilizedand suspended in various buffers prior to chromatography in Sagarose 4 gel columns. The best results were obtained when fraction I was chromatographed in 0.2 M phosphate buffer (pH 7.5). The column gave a good, distinct separation of both high molecular weight material, fraction A, and low molecular weight material, fraction B (Fig. 6) . The total recovered r 3 antiviral activity was distributed between both fractions: 33.5% in fraction A and 66.5% in fraction B; four times more protein was needed in fraction B to attain similar antiviral activity le. Wells 1 and 2 results as in fraction A. ribonucleic acid (DNA). Agar immunodiffusion plates also confirmed the presence of phage material. Antiserum, made against purified whole phage, was placed in the center well. Fraction A, whole phage lysate, and fraction B were placed in the outer wells. A line of identity was seen between fraction A and the phage antigens present in the phage lysate (Fig. 7) . No precipitin line was seen with fraction B. Since it was shown that fraction A contained phage material, it seemed imperative to determine whether this material was involved in the antiviral activity.
In this experiment, a sample of fraction A was mixed with the appropriate amount of X antisera and allowed to react for 10 min at 37 C. The antigen-antibody complex was precipitated by the addition of goat anti-rabbit immunoglobulins and removed by centrifugation. The supernatant fluid was filtered, diluted, and tested in tissue culture. Both rabbit and goat antisera were included in the controls. The results shown in Table 3 indicated that the removal of phage antigens by antiserum made against the whole phage did not diminish the antiviral activity of fraction A. Repeated experiments gave the same results.
Following this observation, fraction I was centrifuged at 105,000 x g for 7 hr to sediment the particulate material. The supernatant fluid which contained mainly DNA and nonsedimentable protein, retained all of the antiviral activity. The nucleic acids present in this sample were removed by the addition of 0.2 volumes of 5% streptomycin sulfate solution. The mixture was allowed to react for 1 hr in the cold and then was centrifuged prior to chromatography on a Sephadex G-25 column equilibrated with 0.05 M Trischloride buffer (pH 8.6). The results of this filtration are shown in Fig. 8 . The antiviral activity resided mainly in the last peak. It could be concluded from this data that the antiviral activity is in the dialyzable low molecular weight fraction and that such material, which is associated with the high molecular weight fraction, is released after treatment with streptomycin sulfate.
Summary ofpurification. The experimental data show that phagicin can be obtained from lysates as well as from whole infective phage.
In view of this finding, phagicin can now be prepared by the following method: (i) gel filtration of the crude lysate to obtain fraction I; (ii) sonic treatment of fraction I to disrupt the infective phage, followed by centrifugation to remove Antiviral activity. Although it has been shown that phagicin is effective in suppressing growth of vaccinia and herpes simplex viruses, all of the fractions obtained during the purification process were tested against herpes simplex virus in chick embryo monolayers, as described in Materials and Methods. A representative dose response curve of the antiviral activity of the crude lysate is shown in Fig. 9 Thus, phagicin appears to be an internal protein of X phage which is bound to the DNA of the phage, but can be released from the DNA by treatment with streptomycin sulfate.
Internal proteins of other coliphages have been described (8) but, to the best of my knowledge, this is the first time that an internal protein of phage has been shown to possess antiviral activity. It is possible that the antiviral activity occurs through the same metabolic inhibition that is found with T2 internal proteins which inhibit DNA-dependent ribonucleic acid polymerase (1) .
Other types of viral inhibitors from E. coli extracts have been reported, and it is probable that E. coli harbors more than one kind of inhibitor. Carver and Rosen (2) described an extract of E. coli 0111 that inhibited vaccinia and herpes simplex in primary amnion cell cultures. The active component was sensitive to trypsin and was shown to impair the DNA metabolism of the cell. The antiviral compound described by Vilcek (11) in E. coli is a protein of cytoplasmic origin. Because of the loss of viral inhibitory activity when actinomycin D is added to the infected cultures, it is possible that this cytoplasmic material acts by inducing interferon in the host. A comparison of these inhibitors and phagicin clearly shows that they are different entities.
Phagicin is a phage internal protein and is obtained from purified phage particles which do not have antiviral activity. The activity is found after disruption of the intact particle. This agrees with the experimental finding that antiserum prepared against intact purified X phage does not diminish the antiviral activity. Phagicin is a potent antiviral agent for herpes simplex and vaccinia in vitro and in established corneal infections. The fact that this internal protein of phage X has been shown to have antiviral activity opens a wide field in virus chemotherapy, since internal proteins of other phages may be effective in suppressing growth of viruses other than herpes simplex and vaccinia.
